Neoadjuvant Opdivo + Chemotherapy Significantly Improves Event-Free Survival in Resectable Lung Cancer
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
For patients with non-metastatic non-small cell lung cancer (NSCLC), surgical resection was once the only hope for cure, but the 30% to 55% postoperative recurrence rate has long been a challenge in medicine. The CheckMate-816 trial results, published in late 2021, brought a breakthrough to this problem: preoperative Opdivo (nivolumab) combined with chemotherapy can significantly improve patients' long-term prognosis.
CheckMate-816: A Milestone in Perioperative Treatment
This trial compared "preoperative immunotherapy combined with chemotherapy" versus "preoperative chemotherapy alone" in patients with stage Ib to IIIa resectable disease.
Key Benefit Analysis:
- Event-Free Survival (EFS) Improvement: Data showed that preoperative Opdivo combination therapy significantly reduced the risk of disease recurrence or progression.
- Pathological Complete Response (pCR): This regimen substantially increased the proportion of patients with "no residual tumor" in postoperative specimens, which is considered an important predictor of long-term improvement.
- Surgical Safety: The study confirmed that adding immunotherapy preoperatively does not increase surgical difficulty or cause surgical delays, demonstrating excellent clinical feasibility.
Clinical Significance: From "Local Treatment" to "Systemic Protection"
Previous treatments focused primarily on postoperative adjuvant chemotherapy, but CheckMate-816 demonstrated the power of "early intervention." By activating systemic T cells through immunotherapy before surgery, potential micrometastatic lesions can be more effectively eliminated.
Medical Team's Comprehensive Recommendations
Japan's leading cancer centers have widely adopted preoperative immunotherapy as a standard option. Through precise preoperative staging assessment and postoperative pathological follow-up at Japanese hospitals, patients can receive the most rigorous "one-stop" perioperative care.
If you are in the evaluation phase before lung cancer resection surgery, understanding the latest preoperative adjuvant regimens is crucial. The Medical Supporter team can assist you in connecting with authoritative Japanese hospitals with extensive experience in perioperative immunotherapy, providing the strongest professional support for your surgical success and postoperative recovery.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4